Published in Adv Virus Res on January 01, 2014
Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol (2014) 0.84
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep (2015) 0.82
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog (2016) 0.80
To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog (2015) 0.79
Malaria - how this parasitic infection aids and abets EBV-associated Burkitt lymphomagenesis. Curr Opin Virol (2016) 0.76
Take your PIKK: tumour viruses and DNA damage response pathways. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
The presence of human papillomavirus and Epstein-Barr virus in male Chinese lichen sclerosus patients: a single center study. Asian J Androl (2016) 0.75
Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency. J Virol (2017) 0.75
Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer. J Oncol (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature (2010) 16.86
Transcriptome genetics using second generation sequencing in a Caucasian population. Nature (2010) 14.85
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
Identification of virus-encoded microRNAs. Science (2004) 12.56
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1981) 7.43
trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol (1986) 6.00
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J (1989) 5.93
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet (2008) 5.08
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 4.87
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA (2006) 4.47
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Mol Cell Biol (1981) 4.39
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 3.88
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 3.59
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J (2000) 3.52
Viruses, microRNAs, and host interactions. Annu Rev Microbiol (2010) 3.30
Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A (1990) 3.29
The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev (1991) 3.24
Liquid-crystalline, phage-like packing of encapsidated DNA in herpes simplex virus. Cell (1991) 3.20
A subset of viral transcripts packaged within human cytomegalovirus particles. Science (2000) 3.19
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A (1991) 3.17
Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity (1998) 3.10
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc Natl Acad Sci U S A (1989) 2.88
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res (2007) 2.74
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med (2008) 2.68
Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A (2007) 2.64
Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells. J Virol (1979) 2.61
Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A (1991) 2.54
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology (1987) 2.53
Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood (2000) 2.53
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res (2008) 2.46
The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog (2012) 2.45
Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol (2004) 2.35
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe (2010) 2.23
Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A (2000) 2.15
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol (2008) 2.10
Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol (1989) 2.10
Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J Virol (1992) 2.09
Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol (2005) 2.08
B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med (1988) 2.00
Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci U S A (2003) 1.96
Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol (1995) 1.92
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol (1999) 1.92
Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe (2010) 1.91
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol (1991) 1.90
Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J (2002) 1.89
Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol (2008) 1.85
Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A (2006) 1.81
Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog (2010) 1.80
A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med (2007) 1.70
Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology (1994) 1.69
oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol (1996) 1.67
Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev (2011) 1.66
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J (2000) 1.66
Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol (2006) 1.62
Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol (1995) 1.62
Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci U S A (2003) 1.60
Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia (2009) 1.59
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell (2012) 1.59
RNAs extracted from herpes simplex virus 1 virions: apparent selectivity of viral but not cellular RNAs packaged in virions. J Virol (2001) 1.57
An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog (2009) 1.56
Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol (2000) 1.55
Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol (2008) 1.51
A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog (2011) 1.51
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol (2010) 1.50
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
Human cytomegalovirus virions differentially incorporate viral and host cell RNA during the assembly process. J Virol (2000) 1.49
Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood (1997) 1.47
Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A (1988) 1.47
AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A (2009) 1.46
LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol (2007) 1.46
Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol (2003) 1.43
Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J Virol (2003) 1.42
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol (1999) 1.41
Viral proteins targeting mitochondria: controlling cell death. Biochim Biophys Acta (2004) 1.40
Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog (2009) 1.39
Alternative splicing dictates translational start in Epstein-Barr virus transcripts. EMBO J (1990) 1.38
An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe (2012) 1.38